Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Capital Expenditures (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Capital Expenditures for 8 consecutive years, with $70000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 3400.0% to $70000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $291000.0, a 781.82% increase, with the full-year FY2025 number at $291000.0, up 781.82% from a year prior.
  • Capital Expenditures was $70000.0 for Q4 2025 at Akebia Therapeutics, down from $77000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $126000.0 in Q2 2025 to a low of $2000.0 in Q3 2024.
  • A 4-year average of $55222.2 and a median of $59000.0 in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 93.22% in 2022, then skyrocketed 3750.0% in 2025.
  • Akebia Therapeutics' Capital Expenditures stood at $59000.0 in 2021, then soared by 93.22% to $114000.0 in 2022, then tumbled by 98.25% to $2000.0 in 2024, then soared by 3400.0% to $70000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Capital Expenditures are $70000.0 (Q4 2025), $77000.0 (Q3 2025), and $126000.0 (Q2 2025).